Ryan Traynor
Papers
1
Total Citations
49
H-Index
1
About
Ryan Traynor is a leading figure in the development of high-throughput mass spectrometry assays for drug discovery, with a particular focus on deubiquitylating enzymes (DUBs). His most cited work, a 2020 study on a MALDI-TOF mass spectrometry–based DUB assay, has garnered 49 citations and represents a significant methodological breakthrough. This assay enables rapid, sensitive, and label-free screening of DUB activity, directly addressing a critical bottleneck in the identification of novel therapeutics for cancer and neurodegenerative diseases. By adapting MALDI-TOF—traditionally used for protein identification—to a high-throughput format, Traynor’s research has provided the pharmaceutical industry with a powerful tool for early-stage drug development. His contributions bridge analytical chemistry and translational medicine, offering a scalable solution for probing ubiquitin biology. This work has been widely recognized for its potential to accelerate the discovery of DUB inhibitors, marking Traynor as an innovator at the intersection of proteomics and drug discovery.
Research Focus
Key Achievements
Top Papers
- 1